BioToxTech Co

BioToxTech Co EPS Growth

The EPS Growth of BioToxTech Co (086040.KQ) as of Nov 12, 2026 is 118.09 %. In the previous year, EPS Growth was -31.77 % — a change of -471.71% (higher).

EPS Growth

118.09 %

YoY

-471.71%

Last updated:

EPS Growth of BioToxTech Co is 2025 118.09 % . EPS Growth of BioToxTech Co was 2024 -31.77 % . It decreases by -471.71% higher compared to the previous year.

The BioToxTech Co EPS Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS Growth
Date
EPS Growth
Jan 1, 2018
159.34 KRW
Jan 1, 2019
-143.65 KRW
Jan 1, 2020
265.23 KRW
Jan 1, 2021
172.19 KRW
Jan 1, 2022
-61.69 KRW
Jan 1, 2023
-278.98 KRW
Jan 1, 2024
-31.77 KRW
Jan 1, 2025
118.09 KRW
The BioToxTech Co EPS Growth history
YEAREPS GrowthYoY
118.09 %-471.71%
-31.77 %-88.61%
-278.98 %+352.21%
-61.69 %-135.83%
172.19 %-35.08%
265.23 %-284.64%
-143.65 %-190.15%
159.34 %+371.97%
33.76 %-73.37%
126.75 %+821.84%
13.75 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioToxTech Co Stock analysis

What does BioToxTech Co do? Biotoxtech Co., Ltd. generates revenue through non-clinical drug trials, offering safety evaluation research, efficacy evaluation research, and analysis research services. Safety evaluation includes general toxicity, local toxicity, reproductive and development, genotoxicity, immunotoxicity, carcinogenicity, safety pharmacology, ecotoxicology, histopathology, and hematology tests. Efficacy evaluation covers medical supplies, health supplements, and cosmetics. Analysis research provides pharmacokinetics (PK) and toxicokinetics (TK) tests, validation, and bio analysis services. The company serves clients requiring preclinical testing for pharmaceuticals, health products, and cosmetics. The firm expanded its operations by acquiring a 60% stake in a newly established subsidiary on March 13, 2013. This strategic move enhances its capacity to deliver comprehensive research services. Clients include pharmaceutical companies, health supplement manufacturers, and cosmetic brands seeking regulatory compliance and product safety validation before market entry. Biotoxtech's service portfolio targets the pharmaceutical, health supplement, and cosmetic industries. Its safety and efficacy testing ensures products meet regulatory standards, supporting clients in developing safe and effective formulations. The company's analysis research further aids in optimizing drug delivery and performance through PK and TK assessments. BioToxTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioToxTech Co stock

EPS Growth of BioToxTech Co is 118.09 % in 2025.

On Eulerpool you can find the complete historical development of EPS Growth BioToxTech Co since 2006 – with annual values, charts, and detailed analysis.

EPS growth measures the percentage change in earnings per share. It accounts for both profit changes and share count changes.

To evaluate EPS Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EPS Growth.

EPS Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EPS Growth's BioToxTech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — BioToxTech Co

All Key Metrics — BioToxTech Co